Release Details

A scientist inside the laboratory testing specimens

Biogen to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

December 19, 2023

Cambridge, MA, Biogen, Inc. (Nasdaq: BIIB) announced today that Christopher A. Viehbacher, President and Chief Executive Officer, will participate in a fireside chat during the 42nd Annual J.P. Morgan Healthcare Conference. The webcast will be live on Monday, January 8, 2024, at 2:15 p.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at An archived version of the webcast will be available for at least 30 days following the presentation.

About Biogen
Founded in 1978, Biogen is a leading global biotechnology company that has pioneered multiple breakthrough innovations including a broad portfolio of medicines to treat multiple sclerosis, the first approved treatment for spinal muscular atrophy, and two co-developed treatments to address a defining pathology of Alzheimer’s disease, the first treatment to target a genetic form of ALS, the first oral treatment approved for postpartum depression, and the first approved treatment for Friedreich’s ataxia. Biogen is advancing a pipeline of potential novel therapies across neurology, neuropsychiatry, specialized immunology and rare diseases and remains acutely focused on its purpose of serving humanity through science while advancing a healthier, more sustainable and equitable world.

We routinely post information that may be important to investors on our website at Follow us on social media - FacebookLinkedIn, X, YouTube.

Karen Jewell
Investor Relations

Stockholder Communications icon

Stockholder Communications

E-mail Alerts icon

E-mail Alerts

FAQs icon